Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity - PubMed (original) (raw)
. 2001 Jul 1;61(13):5132-6.
Affiliations
- PMID: 11431351
Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity
O Nakano et al. Cancer Res. 2001.
Abstract
Tumor-infiltrating lymphocytes, particularly CD8(+) T cells, could be a manifestation of antitumor immunity. We clinicopathologically analyzed the biological significance of tumor-infiltrating lymphocytes in 221 patients with renal cell carcinoma without preoperative treatments. More abundant infiltration of tumor tissue not only by CD8(+) but also CD4(+) T cells was associated with shorter survival of the patients, because of the positive correlation between the number of lymphocytes and representative tumor grade factors. This suggests that immune cell reactions are more pronounced as the tumor grade/biological malignancy progresses, probably because of increased antigenicity of tumor cells. We next analyzed the proliferative activity of CD8(+) T cells that infiltrated in tumor cell nests, which could also reflect antitumor immunity. Higher labeling index of Ki-67, a proliferation-associated antigen, among CD8(+) T cells in contact to tumor cells was associated with a longer survival by both uni- and multivariate analyses. Our data in human renal cell carcinoma suggest that infiltration of tumor tissue by T cells itself does not denote the efficacy of antitumor immunity because of its dependence on the biological malignancy of tumor cells, but infiltration of tumor tissue by CD8(+) T cells bearing more pronounced proliferative activity could reflect effective antitumor immunity. This concept would be important for future immunotherapy of human cancer.
Similar articles
- Intratumoral CXCL13+CD8+T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma.
Dai S, Zeng H, Liu Z, Jin K, Jiang W, Wang Z, Lin Z, Xiong Y, Wang J, Chang Y, Bai Q, Xia Y, Liu L, Zhu Y, Xu L, Qu Y, Guo J, Xu J. Dai S, et al. J Immunother Cancer. 2021 Feb;9(2):e001823. doi: 10.1136/jitc-2020-001823. J Immunother Cancer. 2021. PMID: 33589528 Free PMC article. - Tumor-infiltrating CD39+CD8+ T cells determine poor prognosis and immune evasion in clear cell renal cell carcinoma patients.
Qi Y, Xia Y, Lin Z, Qu Y, Qi Y, Chen Y, Zhou Q, Zeng H, Wang J, Chang Y, Bai Q, Wang Y, Zhu Y, Xu L, Chen L, Kong Y, Zhang W, Dai B, Liu L, Guo J, Xu J. Qi Y, et al. Cancer Immunol Immunother. 2020 Aug;69(8):1565-1576. doi: 10.1007/s00262-020-02563-2. Epub 2020 Apr 18. Cancer Immunol Immunother. 2020. PMID: 32306075 Free PMC article. - CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers.
Wakabayashi O, Yamazaki K, Oizumi S, Hommura F, Kinoshita I, Ogura S, Dosaka-Akita H, Nishimura M. Wakabayashi O, et al. Cancer Sci. 2003 Nov;94(11):1003-9. doi: 10.1111/j.1349-7006.2003.tb01392.x. Cancer Sci. 2003. PMID: 14611679 Free PMC article. - Barriers to immune cell infiltration in tumors.
Melssen MM, Sheybani ND, Leick KM, Slingluff CL Jr. Melssen MM, et al. J Immunother Cancer. 2023 Apr;11(4):e006401. doi: 10.1136/jitc-2022-006401. J Immunother Cancer. 2023. PMID: 37072352 Free PMC article. Review. - Role of CD8+ T lymphocyte cells: Interplay with stromal cells in tumor microenvironment.
Xie Q, Ding J, Chen Y. Xie Q, et al. Acta Pharm Sin B. 2021 Jun;11(6):1365-1378. doi: 10.1016/j.apsb.2021.03.027. Epub 2021 Apr 24. Acta Pharm Sin B. 2021. PMID: 34221857 Free PMC article. Review.
Cited by
- The roles of tertiary lymphoid structures in genitourinary cancers: molecular mechanisms, therapeutic strategies, and clinical applications.
Yang J, Xiong X, Zheng W, Xu H, Liao X, Wei Q, Yang L. Yang J, et al. Int J Surg. 2024 Aug 1;110(8):5007-5021. doi: 10.1097/JS9.0000000000001939. Int J Surg. 2024. PMID: 38978471 Free PMC article. Review. - The Evolving Landscape of Biomarkers for Immune Checkpoint Blockade in Genitourinary Cancers.
Seema Mustafa, Jansen CS, Jani Y, Evans S, Zhuang TZ, Brown J, Nazha B, Master V, Bilen MA. Seema Mustafa, et al. Biomark Insights. 2024 May 31;19:11772719241254179. doi: 10.1177/11772719241254179. eCollection 2024. Biomark Insights. 2024. PMID: 38827239 Free PMC article. Review. - Immunomodulatory Precision: A Narrative Review Exploring the Critical Role of Immune Checkpoint Inhibitors in Cancer Treatment.
Qiu J, Cheng Z, Jiang Z, Gan L, Zhang Z, Xie Z. Qiu J, et al. Int J Mol Sci. 2024 May 17;25(10):5490. doi: 10.3390/ijms25105490. Int J Mol Sci. 2024. PMID: 38791528 Free PMC article. Review. - Function of NEK2 in clear cell renal cell carcinoma and its effect on the tumor microenvironment.
Tang P, Zheng G, Xu C, Yu N, Du J, Hu L, Zhou Z, Zheng Y. Tang P, et al. Medicine (Baltimore). 2024 May 17;103(20):e37939. doi: 10.1097/MD.0000000000037939. Medicine (Baltimore). 2024. PMID: 38758909 Free PMC article. - Effect of HLA Genotype on Anti-PD-1 Antibody Treatment for Advanced Renal Cell Carcinoma in the SNiP-RCC Study.
Tanegashima T, Shiota M, Fujiyama N, Narita S, Habuchi T, Fukuchi G, Takamatsu D, Oda Y, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, Matsuyama H, Obara W, Shinohara N, Fujimoto K, Nozawa M, Ohba K, Ohyama C, Hashine K, Akamatsu S, Kamba T, Mita K, Gotoh M, Tatarano S, Fujisawa M, Tomita Y, Mukai S, Ito K, Tokunaga S, Eto M. Tanegashima T, et al. J Immunol. 2024 Jul 1;213(1):23-28. doi: 10.4049/jimmunol.2300308. J Immunol. 2024. PMID: 38758119 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials